Grepafloxacin: pharmacokinetics and tissue penetration

Area of Science:

• Pharmacology
• Microbiology
• Infectious Diseases

Background:

• Fluoroquinolones are vital for treating respiratory tract infections.
• Understanding drug distribution and concentration is key to therapeutic efficacy.
• Grepafloxacin is a novel broad-spectrum fluoroquinolone.

Purpose of the Study:

• To evaluate the pharmacokinetic and tissue penetration properties of grepafloxacin.
• To compare grepafloxacin's properties with other fluoroquinolones.
• To determine the therapeutic significance of grepafloxacin's pharmacokinetic profile.

Main Methods:

• Pharmacokinetic studies assessing plasma concentrations and area under the concentration-time curve (AUC).
• Tissue penetration studies focusing on lung compartments (alveolar macrophages, bronchial mucosa, epithelial lining fluid).
• In vitro analysis of inhibitory concentrations against key respiratory pathogens.

Main Results:

• Grepafloxacin exhibits a large volume of distribution and superior concentration in lung tissues compared to other fluoroquinolones.
• Achieved plasma concentrations after a 400-mg oral dose exceed inhibitory levels for Staphylococcus aureus, Haemophilus influenzae, and Moraxella catarrhalis.
• While effective against Streptococcus pneumoniae for most of the dosing interval, Enterococcus faecalis may not be fully inhibited at standard doses.

Conclusions:

• Grepafloxacin's pharmacokinetic and tissue penetration characteristics are advantageous for treating respiratory tract infections.
• The drug's profile suggests efficacy in community-acquired pneumonia and acute exacerbations of chronic bronchitis.
• Differences in pharmacokinetics between grepafloxacin and other fluoroquinolones appear to be therapeutically significant.